Abstract
Treatment of locally advanced pancreatic cancer is palliative, based on chemotherapy and according to response, chemoradiotherapy can be applied. The authors summarize three abstracts (#LBA146, #256 and #303) presented on the 2013 ASCO Gastrointestinal Cancers Symposium, which were focused on treatment of locally advanced pancreatic cancer. A discussion is presented about the different chemotherapy or chemoradiotherapy regimens, that move away from gemcitabine-based treatment, and the effort to find less toxic, but efficient therapeutic combinations.
MeSH terms
-
Adenocarcinoma / mortality
-
Adenocarcinoma / pathology*
-
Adenocarcinoma / therapy*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Camptothecin / administration & dosage
-
Camptothecin / adverse effects
-
Camptothecin / analogs & derivatives
-
Clinical Trials, Phase II as Topic
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives
-
Disease Progression
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Fluorouracil / therapeutic use
-
Gemcitabine
-
Humans
-
Leucovorin / administration & dosage
-
Leucovorin / adverse effects
-
Leucovorin / therapeutic use
-
Neoplasm Invasiveness
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / adverse effects
-
Organoplatinum Compounds / therapeutic use
-
Pancreatic Neoplasms / mortality
-
Pancreatic Neoplasms / pathology*
-
Pancreatic Neoplasms / therapy*
-
Randomized Controlled Trials as Topic
Substances
-
Organoplatinum Compounds
-
Deoxycytidine
-
Leucovorin
-
Fluorouracil
-
Camptothecin
-
Gemcitabine
Supplementary concepts
-
FOLFOXIRI protocol
-
Folfox protocol